You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Mitoxantrone slowed progression of disability and reduced relapses in multiple sclerosis

https://doi.org/10.1136/ebm.8.5.148

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) Lancet 360, 2018. Hartung HP, Gonsette R, König N, et al.. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.. ;. :. –25.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In patients with worsening relapsing remitting or secondary progressive multiple sclerosis (MS), is mitoxantrone effective for slowing progression of disability and reducing relapses?

    Design

    Randomised (allocation concealed*), blinded (patients and outcome assessors),* placebo controlled trial with 24 months of follow up.

    Setting

    17 centres in Belgium, Germany, Hungary, and Poland.

    Patients

    194 patients 18–55 years of age who had worsening relapsing-remitting or secondary progressive MS. Additional inclusion criteria included Kurtzke Expanded Disability Status Scale (EDSS) score 3.0–6.0 and worsening by ≥1 EDSS point during the 18 months before enrolment. 188 patients (97%) (mean age 40 y, 52% women) completed follow up.

    Intervention

    Patients were allocated to mitoxantrone, 12 mg/m2 (n=63), 5 mg/m2 (n=66), or placebo (n=65) administered intravenously every 3 months for 24 months. …

    View Full Text

    Footnotes

    • Source of funding: Wyeth-Lederle.

    • For correspondence: Professor HP Hartung, Heinrich-Heine-Universität, Düsseldorf, Germany. hans-peter.hartung{at}uni-duesseldorf.de

    • Abstract and commentary also appear in ACP Journal Club.

    • ↵* See glossary.